WST West Pharmaceutical Services
Permanent stock page ↗Health Care · S&P 500
Next earnings: not announced yet
What 16 analyst firms say about West Pharmaceutical Services: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
15 rated views · 16 analyst/firm records · 16 firms
Radar score
- S&P 500 · Top Picks · 6MBelow the Radar threshold of 8058
- S&P 500 · Safest consensus · 6MBelow the Radar threshold of 8066
Recent analyst activity · last 90 days
Our tracked history has 12 reports on WST from 8 analyst firms in the last 90 days (16 firms in the past year).
Comparing each firm's latest target with its previous one: 5 raised their price target and 2 have their first observed target in the past year.
Ratings, latest available report against the previous one: 1 upgrade and 0 downgrades.
Latest observed target change: Barclays raised its target from $440.00 (set 7 Oct 2026) to $500.00 on 30 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Luke Sergott | Buy | 30 Oct 2026 | 500.00 USD |
| BNP Paribas Exane | Curtis Moiles | Buy | 13 Jul 2026 | Conflicting reports · excluded |
| Citigroup | Joanne Wuensch | Buy | 30 Oct 2026 | 494.00 USD |
| DBS | Nico Chen | Buy | 28 Jan 2026 | 320.00 USD |
| Deutsche Bank | Justin Bowers | Buy | 13 Feb 2026 | 315.00 USD |
| Evercore ISI | Daniel Markowitz | Buy | 7 Oct 2026 | Conflicting reports · excluded |
| Jefferies | David H Windley | Buy | 24 Jul 2026 | 410.00 USD |
| KeyBanc Capital Markets | Paul Knight | Buy | 2 Jul 2026 | 390.00 USD |
| Morgan Stanley | Kallum Titchmarsh | Buy | 22 Sep 2026 | 400.00 USD |
| Redburn | Jamie Clark | Buy | 24 Jul 2026 | Conflicting reports · excluded |
| Stephens | Steven Etoch | Buy | 2 Jun 2026 | Conflicting reports · excluded |
| TD Cowen | Brendan Smith | Buy | 30 Oct 2026 | 500.00 USD |
| UBS | Doug Schenkel | Buy | 9 Sep 2026 | Conflicting reports · excluded |
| Weiss Ratings | Unnamed analyst | — | 7 Aug 2026 | — |
| Wolfe Research | Mike Polark | Buy | 30 Oct 2026 | 460.00 USD |
| Data feed RESEARCH | Research Team | Hold | 12 Aug 2026 | 381.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 04:04 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.